Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ginseng meetings

This article was originally published in The Tan Sheet

Executive Summary

The Department of the Interior's Fish & Wildlife Service will host three public meetings to collect comment on American ginseng, according to a notice in the Federal Register Dec. 29. The findings will be used to gather information for the agency's 2006 findings on the export of American ginseng roots, for the issuance of permits under the Convention on International Trade in Endangered Species of Wild Fauna & Flora (CITES). The Fish & Wildlife Service changed the legal age for export of American ginseng from a five-year old plant to a 10-year old plant in August, which prompted industry members such as the American Herbal Products Association to voice concerns about the rule's economic effect on harvesters (1"The Tan Sheet" Aug. 15, 2005, p. 12). The meetings will be held in Moon Township, Penn. Jan. 31, Asheville, N.C. Feb. 10 and Indianapolis, Ind. Feb. 15...

You may also be interested in...



Ginseng Export Finding May Cause “Significant” Drop In Wild Harvest – AHPA

The U.S. Department of Interior Fish & Wildlife Services' finding on the export of whole wild American ginseng will affect the entire whole-plant ginseng harvest for the next five years, says the American Herbal Products Association

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 

 

Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

Topics

UsernamePublicRestriction

Register

PS098984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel